Indications for INFED:
Iron deficiency where oral therapy is unsatisfactory or impossible.
Adults and Children:
<4mos: not recommended. Give by IV or deep IM inj into upper outer quadrant of buttock only. Administer 0.5mL test dose first; if no signs/symptoms of anaphylactic-type reactions, may give full therapeutic dose. ≥4mos: Iron deficiency anemia: determine total dose based on hemoglobin and body weight (see full labeling). Iron replacement for blood loss: Replacement iron (in mg) = blood loss (in mL) × hematocrit. Max daily doses: <5kg: 0.5mL (25mg), <10kg: 1mL (50mg), ≥10kg: 2mL (100mg).
Anemias not associated with iron deficiency.
Risk for anaphylactic-type reactions.
Monitor for signs/symptoms of anaphylactic-type reactions, esp. in patients with history of drug allergies, asthma; have epinephrine available. Avoid large IV doses: higher incidence of adverse events. Severe hepatic impairment. Avoid during acute phase of infectious kidney disease. Dialysis. Cardiovascular disease. May reactivate quiescent rheumatoid arthritis. Neonates. Pregnancy. Nursing mothers.
Concomitant ACE inhibitors may increase the risk for anaphylactic-type reactions. May falsely elevate serum bilirubin or decrease serum calcium levels.
See full labeling. Anaphylactic reactions (may be fatal; even if test dose was tolerated), cardiovascular events, pruritus, GI upset, arthralgia, arthritis, inj site reactions, others; possible IM inj site tumors, sepsis in neonates.
Generic Drug Availability: